相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Monitoring Response to Antiangiogenic Therapy in Non-Small Cell Lung Cancer Using Imaging Markers Derived from PET and Dynamic Contrast-Enhanced MRI
Adrianus J. de Langen et al.
JOURNAL OF NUCLEAR MEDICINE (2011)
Mechanisms of mTOR inhibitor resistance in cancer therapy
Jennifer S. Carew et al.
TARGETED ONCOLOGY (2011)
AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity
Christine M. Chresta et al.
CANCER RESEARCH (2010)
New inhibitors of the mammalian target of rapamycin signaling pathway for cancer
Sebastien Albert et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2010)
Akt inhibitors in clinical development for the treatment of cancer
Sumanta Kumar Pal et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2010)
Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2
Mamta Gupta et al.
BLOOD (2009)
Advances in Development of Phosphatidylinositol 3-Kinase Inhibitors
Dexin Kong et al.
CURRENT MEDICINAL CHEMISTRY (2009)
An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1
Carson C. Thoreen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Targeting the phosphoinositide 3-kinase pathway in cancer
Pixu Liu et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
Morris E. Feldman et al.
PLOS BIOLOGY (2009)
Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors
Anne O'Donnell et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Antitumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-Deficient glioblastoma
Tim F. Cloughesy et al.
PLOS MEDICINE (2008)
Current development of mTOR inhibitors as anticancer agents
Sandrine Faivre et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB
DD Sarbassov et al.
MOLECULAR CELL (2006)
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
KE O'Reilly et al.
CANCER RESEARCH (2006)
Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer
E Raymond et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells
A Boulay et al.
CANCER RESEARCH (2004)
The phosphatidylinositol 3-kinase-AKT pathway in human cancer
I Vivanco et al.
NATURE REVIEWS CANCER (2002)
分享论文
